Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7473440 | 0.98 | LMNA (0.62) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL5317893 | 0.91 | TSHR (0.50) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9632054 | 0.89 | LMNA (0.51) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9632837 | 0.88 | LMNA (0.50) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL1803675 | 0.87 | PKM (0.56) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL10639502 | 0.87 | PKM (0.53) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL28110078 | 0.87 | TAAR1 (0.63) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL28732677 | 0.87 | PKM (0.55) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL1803678 | 0.86 | PKM (0.55) | KDM4EATMTSHRCYP1A2CYP3A4 | |
| SCHEMBL8167206 | 0.86 | PKM (0.51) | KDM4EATMTSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2408769-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | Glaxo Group Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106016-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-09-23 | — | — | WO | disclosed |
| US-7638649-B2 | Method of preparation of (R)-(−)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | ZENTIVA, K.S. (CZ) | 2009-12-29 | — | — | US | disclosed |
| EP-1603866-B1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD (IN) | 2009-04-29 | — | — | EP | disclosed |
| US-20080319225-A1 | Method of Preparation of (R)-(-)-5(2-Aminopropyl)-2-Methoxybenzenesulfonamide | ZENTIVA, A.S. (CZ) | 2008-12-25 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1335902-B1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-7384963-B2 | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| WO-2003032986-A1 | 2' -METHYL-5-(1,3,4-OXADIAZOL-2-YL)-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-6511989-B2 | For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-28 | — | — | US | disclosed |
| US-6472413-B2 | FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| WO-2002036556-A2 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036565-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1183236-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| US-6350778-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-26 | — | — | US | disclosed |
| WO-2000071513-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | KDM4E 2022/4885ATM 1166/4885TSHR 4376/4885 |
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, HCN3, CACNA1E | KDM4E 579/4885ATM 3749/4885TSHR 2480/4885 |
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, KCNJ1, KCNA1 | KDM4E 476/4885ATM 1809/4885TSHR 1847/4885 |
| US-20080319225-A1 | Method of Preparation of (R)-(-)-5(2-Aminopropyl)-2-Methoxybenzenesulfonamide | NPSR1, TPSAB1, TPSB2 | KDM4E 2540/4885ATM 1348/4885TSHR 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.